BioSyent, Inc. (RX.V)
17.79
-0.21
(-1.17%)
CAD |
TSXV |
Nov 13, 16:00
BioSyent Enterprise Value : 195.94M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 195.94M |
| November 12, 2026 | 198.32M |
| November 11, 2026 | 199.46M |
| November 10, 2026 | 197.19M |
| November 09, 2026 | 197.19M |
| November 06, 2026 | 194.92M |
| November 05, 2026 | 190.84M |
| November 04, 2026 | 188.68M |
| November 03, 2026 | 185.28M |
| November 02, 2026 | 187.55M |
| October 30, 2026 | 188.00M |
| October 29, 2026 | 185.06M |
| October 28, 2026 | 186.98M |
| October 27, 2026 | 183.47M |
| October 26, 2026 | 182.56M |
| October 23, 2026 | 186.42M |
| October 22, 2026 | 186.42M |
| October 21, 2026 | 187.78M |
| October 20, 2026 | 186.53M |
| October 19, 2026 | 184.60M |
| October 16, 2026 | 183.92M |
| October 15, 2026 | 175.87M |
| October 14, 2026 | 174.40M |
| October 13, 2026 | 175.30M |
| October 09, 2026 | 188.68M |
| Date | Value |
|---|---|
| October 08, 2026 | 186.08M |
| October 07, 2026 | 185.85M |
| October 06, 2026 | 184.71M |
| October 05, 2026 | 185.40M |
| October 02, 2026 | 183.92M |
| October 01, 2026 | 181.31M |
| September 30, 2026 | 183.58M |
| September 29, 2026 | 184.49M |
| September 28, 2026 | 184.49M |
| September 25, 2026 | 177.91M |
| September 24, 2026 | 181.88M |
| September 23, 2026 | 181.77M |
| September 22, 2026 | 192.54M |
| September 21, 2026 | 175.64M |
| September 18, 2026 | 172.58M |
| September 17, 2026 | 176.32M |
| September 16, 2026 | 176.55M |
| September 15, 2026 | 175.42M |
| September 14, 2026 | 173.94M |
| September 11, 2026 | 171.79M |
| September 10, 2026 | 171.67M |
| September 09, 2026 | 172.13M |
| September 08, 2026 | 173.94M |
| September 04, 2026 | 175.30M |
| September 03, 2026 | 174.28M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| HLS Therapeutics, Inc. | 154.12M |
| Bausch Health Cos., Inc. | 31.74B |
| Cipher Pharmaceuticals, Inc. | 336.68M |
| Revive Therapeutics Ltd. | 6.520M |
| Knight Therapeutics, Inc. | 1.082B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 2.849M |
| Revenue (Quarterly) | 19.87M |
| Total Expenses (Quarterly) | 17.02M |
| EPS Diluted (Quarterly) | 0.245 |
| Gross Profit Margin (Quarterly) | 65.02% |
| Profit Margin (Quarterly) | 14.34% |
| Earnings Yield | 4.82% |
| Operating Earnings Yield | 6.31% |
| Normalized Earnings Yield | 4.818 |